Skip to content
#gene editing Review Open access

Transforming cardiac amyloidosis care: navigating the evolving diagnostic and therapeutic landscape.

Nov 2026 · Netherlands Heart Journal · 0 citations · 32 references
Medicine

TL;DR

This review provides a comprehensive overview of the diagnostic pathway, including (AI-enabled) electrocardiography analysis, (non-)invasive imaging modalities, biomarkers, and genetic testing, and emerging therapeutic strategies are discussed.

Abstract

Amyloidosis comprises a group of systemic disorders caused by extracellular deposition of misfolded precursor proteins, leading to progressive organ dysfunction. Cardiac amyloidosis, particularly transthyretin-related amyloid cardiomyopathy (ATTR-CM) has transitioned from a rare and underdiagnosed condition to a treatable disease, driven by major advances in diagnostic imaging, increased disease awareness, and the approval of disease-modifying therapies. These therapies target transthyretin (TTR) stabilization and amyloid production or deposition and have led to an evolving therapeutic landscape. As therapeutic efficacy is greatest in earlier disease stages, timely recognition is crucial. Effective management of ATTR-CM requires structured screening of high-risk populations, multidisciplinary collaboration, and longitudinal follow-up. This review provides a practical, clinician-focused framework that addresses clinical presentation and "red flags" to facilitate early detection. It offers a comprehensive overview of the diagnostic pathway, including (AI-enabled) electrocardiography analysis, (non-)invasive imaging modalities, biomarkers, and genetic testing. Additionally, emerging therapeutic strategies are discussed, encompassing supportive heart failure management, amyloid-specific treatments such as TTR stabilizers and gene silencers, and novel approaches including fibril depletion and gene-editing therapies. As the therapeutic paradigm shifts from disease stabilization toward potential reversal, early diagnosis and personalized treatment strategies are essential to improve prognosis and quality of life in patients with cardiac amyloidosis.

Read PDF

Similar papers

Review Open access 2026

Optimal non-invasive diagnostic approaches and disease-modifying therapeutic strategies in cardiac amyloidosis (literature review)

Cardiac amyloidosis is an infiltrative cardiomyopathy caused by extracellular deposition of amyloid fibrils in the myocardium, leading to progressive restrictive dysfunction. The main clinical challenge is delayed diagnosis and differentiation between transthyretin amyloidosis and immunoglobulin light-chain amyloidosis...

K. A. Loginova, Elizaveta S. Aldankova, M. V. Petrov et al. · 0 citations
#gene editing Review Open access Nov 2026

Transthyretin Amyloid Cardiomyopathy: Contemporary Pharmacological Management

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive infiltrative cardiomyopathy increasingly recognised as a cause of heart failure. Advances in the understanding of its pathophysiology have enabled the development of targeted therapies, making ATTR-CM a paradigm of precision medicine in cardiology. Current...

M. T. Basurte-Elorz, Gemma Lacuey-Lecumberri, N. Mora-Ayestarán · 0 citations
Review Open access Oct 2026

Heterogeneity in cardiac amyloidosis care across Europe: a key opinion leader survey

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a form of cardiac amyloidosis characterized by misfolding and subsequent depositions of transthyretin (TTR) in the heart, leading to heart failure. ATTR-CM has recently become a treatable condition with the introduction of disease-modifying therapies (DMT) such as...

L. Kieviet, L. Rekker, D. Breucker et al. · 0 citations
#gene editing Review Open access Sep 2026

Pathophysiology and Comprehensive Pharmacological Management of ATTR Cardiac Amyloidosis: Knowledge Gaps, Ongoing Clinical Trials, and Future Research Directions

Cardiac amyloidosis is an increasingly recognized cause of heart failure in the setting of progressive restrictive cardiomyopathy, particularly among older adults, males, and individuals of African descent, with remarkable advances in the therapeutic landscape, but substantial knowledge gaps persist.

S. Bains, Harry Atwal, Ashbir Sidhu et al. · 0 citations
Review Oct 2026

Diagnostic challenges in light chain (AL) amyloidosis for high-risk patients.

INTRODUCTION Immunoglobulin light-chain (AL) amyloidosis is associated with high early mortality, particularly when the diagnosis occurs after advanced cardiac or multiorgan dysfunction has developed. Existing reviews have addressed diagnosis and management, but the evolving concept of high-risk disease in the modern t...

Mahmoud Massalha, Tamer Hellou, M. Gertz · 0 citations
Review Oct 2026

Arrhythmias in patients with transthyretin cardiac amyloidosis and the impact of contemporary disease-modifying therapies.

Transthyretin cardiac amyloidosis (ATTR-CM) is an increasingly recognized infiltrative cardiomyopathy characterized by extracellular deposition of misfolded transthyretin fibrils, leading to progressive myocardial stiffening, electrical remodeling, and conduction-system disease. These pathophysiological changes create...

I. Ntalas, Panagiotis Korantzopoulos, C. Goudis et al. · 1 citation

Related blog posts

Microsoft Research Blog Nov 12, 2026

Microsoft Research Focus – Edition #98

What's new in research at Microsoft? Host Anson Ho explores the latest, including AI-powered universal translation, a breakthrough in a 31-year-old mathematics challenge, and advances making AI coding agents faster and more efficient.  The post Microsoft Research Focus – Edition #98 appeared first on Microsoft Research.

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.